These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 29499996)

  • 21. Screening aortic drug treatments through arterial compliance measurements.
    Rentschler ME; Baxter BT
    Curr Vasc Pharmacol; 2008 Oct; 6(4):250-7. PubMed ID: 18855713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A retrospective study: Factors associated with the risk of abdominal aortic aneurysm rupture.
    Gokani VJ; Sidloff D; Bath MF; Bown MJ; Sayers RD; Choke E
    Vascul Pharmacol; 2015; 65-66():13-6. PubMed ID: 25485708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging Pharmacological Treatments to Prevent Abdominal Aortic Aneurysm Growth and Rupture.
    Fraga-Silva RA; Trachet B; Stergiopulos N
    Curr Pharm Des; 2015; 21(28):4000-6. PubMed ID: 26306842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological Therapy of Abdominal Aortic Aneurysm: An Update.
    Wang YD; Liu ZJ; Ren J; Xiang MX
    Curr Vasc Pharmacol; 2018 Jan; 16(2):114-124. PubMed ID: 28412911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological therapy for patients with abdominal aortic aneurysm.
    Assar AN
    Expert Rev Cardiovasc Ther; 2009 Aug; 7(8):999-1009. PubMed ID: 19673677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study.
    Hackam DG; Thiruchelvam D; Redelmeier DA
    Lancet; 2006 Aug; 368(9536):659-65. PubMed ID: 16920471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can pharmacologic agents slow abdominal aortic aneurysm growth?
    Samson R
    Semin Vasc Surg; 2012 Mar; 25(1):25-8. PubMed ID: 22595478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Editor's Choice - Pharmaceutical Management of Small Abdominal Aortic Aneurysms: A Systematic Review of the Clinical Evidence.
    Kokje VB; Hamming JF; Lindeman JH
    Eur J Vasc Endovasc Surg; 2015 Dec; 50(6):702-13. PubMed ID: 26482507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A combination of statins and beta-blockers is independently associated with a reduction in the incidence of perioperative mortality and nonfatal myocardial infarction in patients undergoing abdominal aortic aneurysm surgery.
    Kertai MD; Boersma E; Westerhout CM; Klein J; Van Urk H; Bax JJ; Roelandt JR; Poldermans D
    Eur J Vasc Endovasc Surg; 2004 Oct; 28(4):343-52. PubMed ID: 15350554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perioperative management of endovascular abdominal aortic aneurysm repair: update 2010.
    Smaka TJ; Cobas M; Velazquez OC; Lubarsky DA
    J Cardiothorac Vasc Anesth; 2011 Feb; 25(1):166-76. PubMed ID: 21093297
    [No Abstract]   [Full Text] [Related]  

  • 31. Primary prevention of myocardial infarction: putting the evidence to use.
    Herzog E; Javed F
    Arch Intern Med; 2010 Aug; 170(15):1381-2. PubMed ID: 20696965
    [No Abstract]   [Full Text] [Related]  

  • 32. Current Status and Perspectives on Pharmacologic Therapy for Abdominal Aortic Aneurysm.
    Yoshimura K; Morikage N; Nishino-Fujimoto S; Furutani A; Shirasawa B; Hamano K
    Curr Drug Targets; 2018; 19(11):1265-1275. PubMed ID: 29284386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors associated with small abdominal aortic aneurysm expansion rate.
    Bhak RH; Wininger M; Johnson GR; Lederle FA; Messina LM; Ballard DJ; Wilson SE;
    JAMA Surg; 2015 Jan; 150(1):44-50. PubMed ID: 25389641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Re: Secondary medical prevention in patients with peripheral arterial disease.
    Schouten O; Welten GM; Bax JJ; Poldermans D
    Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):59-60. PubMed ID: 17719805
    [No Abstract]   [Full Text] [Related]  

  • 35. Screening, diagnosis and advances in aortic aneurysm surgery.
    Daly KJ; Torella F; Ashleigh R; McCollum CN
    Gerontology; 2004; 50(6):349-59. PubMed ID: 15477695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal medical management of peripheral arterial disease.
    Rice TW; Lumsden AB
    Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction.
    Halvorsen S; Jortveit J; Hasvold P; Thuresson M; Øie E
    BMC Cardiovasc Disord; 2016 May; 16():115. PubMed ID: 27246583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Statin use and rupture of abdominal aortic aneurysm.
    Wemmelund H; Høgh A; Hundborg HH; Thomsen RW; Johnsen SP; Lindholt JS
    Br J Surg; 2014 Jul; 101(8):966-75. PubMed ID: 24849021
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can statins suppress the development of abdominal aortic aneurysms? A review of the current evidence.
    Saratzis A; Kitas GD; Saratzis N; Melas N
    Angiology; 2010 Feb; 61(2):137-44. PubMed ID: 19625274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of secondary medical prevention after primary vascular reconstruction: studies on usage and effectiveness.
    Høgh AL
    Dan Med J; 2012 Sep; 59(9):B4514. PubMed ID: 22951205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.